natgillin/translations-raw huggingface dataset:
Prescribers - a letter including the following dossiers:
zdravniki, ki predpisujejo zdravilo – dopis, ki bo vključeval naslednje sklope:
Prescribers and patients should be alert to this possibility in the event of severe flushing reactions (see sections 4.2, 4.5 and 4.8).
Zdravnike, ki zdravilo predpisujejo, in bolnike, je treba opozoriti na možnost hudih reakcij vročinskega oblivanja (glejte poglavja 4.2, 4.5 in 4.8).
Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
Predpisovalci zdravila se morajo zavedati tveganja lažno negativnih rezultatov tuberkulinskega kožnega testa, posebej pri bolnikih, ki so hudo bolni ali imajo oslabljen imunski sistem.
Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
Zdravnike opozarjamo, da so izvidi tuberkulinskega kožnega testa lahko lažno negativni, še posebej pri bolnikih, ki so močno bolni ali imajo zmanjšan imunski odziv.
Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
Zdravnike predpisovalce opominjamo na nevarnost lažno negativnih rezultatov tuberkulinskega kožnega testa, še posebej pri bolnikih, ki so hudo bolni ali imunokompromitirani.
Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
Zdravnike tudi opozarjamo na tveganje za lažno negativen izvid tuberkulinskega kožnega testa, še posebej pri bolnikih, ki so zelo bolni ali imajo oslabljen imunski sistem.
Prescribers are reminded that the use of doses above 100 mg/kg/day are not recommended (see sections 4.8 and 4.9).
Predpisovalci zdravila se morajo zavedati, da uporaba odmerkov večjih od 100 mg/kg/dan ni priporočljiva (glejte poglavji 4.8 in 4.9).
Prescribers of Flixabi for paediatric Crohn’s disease and paediatric ulcerative colitis shall additionally be made aware:
Predpisovalci zdravila Flixabi za pediatrično Crohnovo bolezen in pediatrični ulcerozni kolitis morajo biti seznanjeni tudi z naslednjim:
Prescribers of Remicade for paediatric Crohn’s disease and paediatric ulcerative colitis shall additionally be made aware:
Predpisovalci zdravila Remicade pediatričnim bolnikom s Crohnovo boleznijo ali ulceroznim kolitisom morajo biti dodatno seznanjeni še z naslednjim:
Prescribers of Remsima for paediatric Crohn’s disease and paediatric ulcerative colitis shall additionally be made aware:
Predpisovalci zdravila Remsima pediatričnim bolnikom s Crohnovo boleznijo ali ulceroznim kolitisom, morajo biti dodatno seznanjeni še z naslednjim:
Prescribers should consider official guidance on the appropriate use of antibiotics.
Zdravniki, ki predpisujejo zdravilo, morajo upoštevati uradne smernice za ustrezne uporabo antibiotikov.
Prescribers should consider official guidance on the use of antibacterial agents.
Zdravniki, ki predpisujejo zdravilo, morajo upoštevati uradne smernice o uporabi protibakterijskih zdravil.
Prescribers should consider official guidance on the use of antibiotics.
Zdravniki, ki predpisujejo zdravilo, morajo upoštevati uradne smernice o uporabi protibakterijskih zdravil.
Prescribers should draw the attention of paediatric patients and their parent/carers to the advice in the Packaging Leaflet on preventing heatstroke and overheating in children as provided.
Zdravniki, ki zdravilo predpisujejo, morajo pediatrične bolnike in njihove starše/skrbnike opozoriti na navedene nasvete v navodilu za uporabo glede preprečevanja vročinske kapi in pregretja pri otrocih.
Prescribers should exercise caution in considering the use of Humira in patients with pre-existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of Humira should be considered if any of these disorders develop.
Pri odločanju za uporabo zdravila Humira pri bolnikih z že prej obstoječimi ali nedavno nastalimi demielinizirajočimi boleznimi osrednjega ali perifernega živčevja je potrebna previdnost; če se razvije katera od teh bolezni, je treba razmisliti o prenehanju zdravljenja z zdravilom Humira.
Prescribers should take into account official guidance on the use of antibiotics.
Zdravniki, ki predpisujejo zdravilo, morajo upoštevati uradne smernice za uporabo antibiotikov.
Prescribers will also receive a patient alert card to give to patients receiving Xarelto containing key safety reminders for patients.
Prejeli bodo tudi opozorilno kartico, namenjeno bolnikom, ki prejemajo zdravilo Xarelto, s ključnimi varnostnimi opozorili zanje.
Prescribing and dispensing restrictions for WCBP
Omejitve za predpisovanje in izdajanje zdravila ženskam v rodni dobi
Prescribing doctor: Phone No:
Zdravnik, ki je predpisal zdravilo:
Prescription of EFFENTORA only by physicians experienced in the management of opioid therapy in cancer patients
Zdravilo EFFENTORA lahko predpisujejo samo zdravniki z izkušnjami v vodenju opioidnega zdravljenja pri bolnikih z rakom
Prescription of EFFENTORA only to critically selected patients with close following on
Zdravilo EFFENTORA je dovoljeno predpisati le kritično izbranim bolnikom s posebnim poudarkom na
Prescription of nitric oxide should be supervised by a physician experienced in cardiothoracic anaesthesia & intensive care.
Predpisovanje dušikovega oksida mora nadzorovati zdravnik z izkušnjami s kardiotorakalno anestezijo in intenzivno nego.
Prescription of nitric oxide should be supervised by a physician experienced in neonatal intensive care.
Predpisovanje dušikovega oksida mora nadzirati zdravnik z izkušnjami v intenzivni negi novorojenčkov.
presence of anti-acid agent in
redstva v pufranih tabletah
Presence of anti-JC virus antibodies
Prisotnost protiteles proti JCV
Presence of baseline NS5A resistance-associated substitutionsc
Prisotnost izhodiščnih substitucij NS5A, povezanih z odpornostjoc
presence of blood in urine, presence of proteins in urine
prisotnost krvi v urinu, prisotnost beljakovin v urinu;
presence of blood or proteins in the urine
prisotnost krvi ali beljakovin v urinu
Presence of cirrhosis
Prisotnost ciroze
Presence of del17p
Prisotnost del17p
presence of potent CYP3A
močnimi zaviralci CYP3A
presence of protein in your urine accompanied by swelling of your body,
beljakovine v seču, ki jih spremlja otekanje telesa,
Presence of red blood cells in the urine
prisotnost rdečih krvničk v urinu
Presence of red blood cells in the urine (may show in your urine tests)
prisotnost rdečih krvnih celic v urinu (to se lahko pokaže pri preiskavah urina)
Presence of severe hepatic disease
huda bolezen jeter;
Presence of small air bubbles is acceptable.
Prisotnost majhnih zračnih mehurčkov je sprejemljiva.
Presence of superficial-vein thrombosis greater than 3 cm from the sapheno-femoral junction should be confirmed and concomitant DVT should be excluded by compression ultrasound or objective methods prior to initiating treatment of fondaparinux.
Pred začetkom zdravljenja s fondaparinuksom je treba s kompresijskim ultrazvokom ali drugimi objektivnimi metodami potrditi, da je povrhnja venska tromboza več kot 3 cm daleč od safeno-femoralnega spoja in da ni sočasne globoke venske tromboze.
Presence of superficial-vein thrombosis greater than 3 cm from the sapheno-femoral junction should be confirmed and concomitant DVT should be excluded by compression ultrasound or objective methods prior to initiating treatment with fondaparinux.
Pred začetkom zdravljenja s fondaparinuksom je treba s kompresijskim ultrazvokom ali drugimi objektivnimi metodami potrditi, da je povrhnja venska tromboza več kot 3 cm daleč od safeno- femoralnega spoja in da ni sočasne globoke venske tromboze.
Presence of t(4;14)
Prisotnost t(4;14)
Presence or history of liver tumours (benign or malignant).
Jetrni tumorji ali jetrni tumorji v anamnezi (benigni ali maligni).
Presence or history of severe hepatic disease as long as liver function values have not returned to normal.
Obstoječa huda bolezen jeter ali huda bolezen jeter v anamnezi, pri kateri se izvidi delovanja jeter niso povrnili na normalne vrednosti.
Presence or history of severe hepatic disease as long as liver function values have not returned to normal.
Obstoječa huda jetrna bolezen ali huda jetrna bolezen v anamnezi, pri kateri se izvidi delovanja jeter niso povrnili na normalne vrednosti.
Presence or risk of arterial thromboembolism (ATE)
Prisotna arterijska trombembolija (ATE) ali tveganje zanjo
Presence or risk of arterial thromboembolism (ATE)
Prisotnost ali tveganje za arterijsko trombembolijo (ATE)
Presence or risk of venous thromboembolism (VTE)
Prisotna venska trombembolija (VTE) ali tveganje zanjo
Presence or risk of venous thromboembolism (VTE)
Prisotna venska trombembolija (VTE) ali tveganje zanjo.
Presence or risk of venous thromboembolism (VTE)
Prisotnost ali tveganje za vensko trombembolijo (VTE)
Present information on the safety of mercaptopurine in pregnancy is conflicting.
Trenutni podatki o varnosti merkaptopurina v nosečnosti niso enotni.
Present this card to every physician or dentist prior to treatment
Preden začnete katero koli zdravljenje pokažite kartico lečečemu zdravniku ali zobozdravniku.
Present this card to health care professionals (doctor, nurse) upon consultation or hospitalization!
V primeru obiska zdravnika ali hospitalizacije to kartico pokažite zdravstvenemu delavcu (zdravniku, medicinski sestri)
PRESENTATION
OBLIKA
PRESENTATION
OPREMA
Presentation
Pakiranje
Presentation 02 (with separate MiniSpike transfer system (CE 0123))
Predstavitev 02 (z ločenim prenosnim sistemom MiniSpike (CE 0123))
Presentation 02 (with separate MiniSpike transfer system)
Pakiranje 02 (z ločenim MiniSpike sistemom za prenos)
Presentation 02 (with separate MiniSpike transfer system):
Pakiranje 02 (z ločenim MiniSpike sistemom za prenos)
Presentation Pack of 1 vial.
Velikost pakiranja Pakiranje z 1 vialo.
Presentation.
Pakiranje
Presentations
Oblike
Presentations:
Oprema:
Presentations:
Pakiranja:
Presented as a volatile spray, this veterinary medicinal product does not require any massage.
Ker je omenjena snov zelo hlapljiva, po uporabi razpršila masaža ni potrebna.
Press a cotton ball over the injection site for 10 seconds.
Na mesto injiciranja za 10 sekund pritisnite blazinico iz vate.
Press an antiseptic wipe over the injection site for a few seconds after the injection
Na mesto injiciranja za nekaj sekund pritisnite antiseptični zloženec.
Press an antiseptic wipe over the injection site for a few seconds after the injection.
Na mesto injiciranja za nekaj sekund pritisnite antiseptični zloženec.
Press and firmly hold the pen against your body until the yellow safety cover is no longer visible.
Pritisnite peresnik ob telo in ga trdno držite, dokler rumeni varnostni ščitnik ni več viden.
PRESS AND HOLD
3 PRITISNITE IN DRŽITE
Press and hold down the dose button until the dose counter returns to 0.
Pritisnite in držite potisni gumb, da se števec odmerka vrne na 0.
Press and hold down the dose button until the dose counter shows 0.
Pritisnite na potisni gumb in ga držite, dokler se števec odmerka ne vrne na 0.
Press and hold in the dose button until the dose counter returns to 0.
Pritisnite in držite potisni gumb, da se števec odmerka vrne na 0.
PRESS and hold tab at the left
PRITISNITE in držite jeziček na levi
Press bottle adaptor into the neck of the bottle.
Vstavite nastavek za plastenko v vrat plastenke.
Press down and turn the cap clockwise as far as it will go (Figure 2b).
Pokrov za zdravilo pritisnite navzdol in ga obračajte v smeri urnega kazalca, dokler gre (slika 2b).
Press down firmly on the patch with the palm of your hand for 10 seconds
Z dlanjo 10 sekund trdno pritiskajte na obliž.
Press down firmly until the side tabs click into position
Čvrsto pritisnite navzdol, dokler stranska jezička ne vskočita v pravi položaj.
Press down on the plunger with your finger.
S prstom pritisnite bat.
Press in the adapter
Namestite nastavek za steklenico
Press IONSYS firmly in place for at least 15 seconds with the sticky side down on the skin of the chest or upper arm of the patient.
Sistem IONSYS za najmanj 15 sekund trdno pritisnite z lepilno stranjo navzdol na kožo na bolnikovih prsih ali nadlahti.
Press on the white button on the side of the nasal spray.
Pritisnite beli gumb ob strani pršila za nos.
Press side tabs inwards using your thumb and middle finger
Pritisnite stranska jezička navznoter s palcem in sredincem.
Press slowly so that this takes approximately 30 seconds.
Bat potiskajte počasi, tako da injiciranje traja približno 30 sekund.
Press the administration system down firmly against the injection area once again.
Ponovno odločno pritisnite aplikacijski sistem navzdol na mestu injiciranja.
Press the administration system firmly onto the skin.
Čvrsto pritisnite aplikacijski sistem na kožo.
Press the administration system onto the skin again within 10 seconds and maintain pressure until the status light resumes slowly flashing orange.
V 10 sekundah ponovno pritisnite aplikacijski sistem na kožo in ohranite pritisk, dokler lučka ne začne počasi utripati oranžno.
Press the blue activation button with your thumb to start the injection.
S palcem pritisnite modri sprožilni gumb, da začnete injicirati.
Press the blue injection button until it is fully depressed –then count slowly to 10 and remove the needle from your skin.
Pritisnite na modri injekcijski gumb do konca, da se zaskoči – potem počasi štejte do 10 in odstranite iglo iz vaše kože.
Press the blue start button for at least 5 seconds.
Pritisnite modro stikalo za vklop in ga zadržite vsaj 5 sekund.
Press the bottle adaptor into the neck of the bottle (as shown on figure below).
Vstavite nastavek za plastenko v vrat plastenke (kot kaže slika spodaj).
Press the button firmly all the way in, while you breathe in through your nose – see picture h.
Močno pritisnite gumb povsem do konca, medtem ko vdihnete skozi nos – glejte sliko h.
Press the button firmly all the way in.
Močno pritisnite gumb povsem do konca noter.
Press the dose button with your thumb until the dose counter returns to 0.
S palcem pritisnite potisni gumb, dokler se števec odmerka ne vrne na 0.
Press the dose knob down as far as it will go and hold it to complete the full injection.
Gumb za odmerek pritisnite navzdol, dokler gre, in držite, dokler injiciranje ni končano.
Press the dose setting knob as far as it will go.
Do konca pritisnite gumb za nastavitev odmerka.
Press the entire patch firmly onto the skin with your fingertips.
Obliž trdno pritisnite na kožo s konicami prstov.
Press the grey button and pull out the insulin blister.
Pritisnite sivi gumb in izvlecite insulinski pretisni omot.
Press the injection button all the way in.
Pritisnite gumb za injiciranje povsem noter.
Press the injection button completely in and discard the insulin.
Pritisnite gumb za injiciranje do konca in zavrzite insulin.
Press the injection button completely in and discard the insulin.
V rezervoarju ni dovolj insulina.
Press the injection button completely in to discard the insulin.
Pritisnite gumb za injiciranje do konca, da boste zavrgli insulin.
Press the injection button in completely to discard the dose and select again.
Pritisnite gumb za injiciranje do konca, da boste odmerek zavrgli, in nastavite znova.
Press the injection button.
Pritisnite injekcijski gumb.
Press the injection site with a small bandage or sterile gauze if necessary for several seconds.
Na mesto injiciranja pritisnite majhen ovoj ali sterilno gazo in jo, če je treba, držite nekaj sekund.
Press the needle safety guard down onto a hard surface such as a table.
Varnostni ščitnik pritisnite ob trdo površino, na primer ob mizo.
Press the patch down firmly until the edges stick well.
Obliž močno pritisnite na kožo, da se robovi dobro prilepijo.
Press the patch down firmly with the palm of your hand for about 20 to 30 seconds to make sure the patch is touching the skin and the edges stick well.
Obliž 20 do 30 sekund močno pritiskajte z dlanjo, da zagotovite, da se dotika kože in da so robovi dobro zalepljeni.
Press the patch firmly in place for at least 30 seconds using the palm of the hand.
Obliž z dlanjo čvrsto pritiskajte na kožo najmanj 30 sekund.
Press the pen firmly against the skin to start the injection.
Injekcijski peresnik močno pritisnite proti koži, da se injiciranje lahko začne.
Press the pen into injection site and hold.
Injekcijski peresnik pritisnite na mesto injiciranja in ga držite.
Press the pen onto the skin to unlock safety guard.
Pritisnite peresnik na kožo, da boste sprostili varnostno zaščito.
Press the plunger slowly until the syringe is empty.
Počasi potiskajte bat, da se injekcijska brizga izprazni.
Press the plunger upwards firmly to release the dose with your thumb while inhaling gently through the nose and then remove the spray container from the nose.
Odmerek sprostite s čvrstim pritiskom palca na bat ter sočasno nežno vdihnite skozi nos, potem pa odstranite vsebnik pršila iz nosu.
Press the plunger very slowly so that the liquid gently runs down the inside of the vial.
Bat zelo previdno potiskajte navzdol, da tekočina počasi teče po notranji steni viale.
Press the pre-filled pen against the skin as shown in Figure 10.
Napolnjeni injekcijski peresnik pritisnite na kožo, kot prikazuje slika 10.
Press the pre-filled pen firmly against the skin.
Napolnjeni injekcijski peresnik čvrsto potisnite v kožo.
Press the pre-filled pen firmly enough against the skin so that the safety cover is fully retracted (see picture 6).
Napolnjeni injekcijski peresnik pritisnite na kožo dovolj močno, da se varnostni pokrovček popolnoma umakne (glejte sliko 6).
Press the pre-filled pen firmly enough against the skin so that the safety cover is fully retracted (see picture 6).
Varnostni pokrovček igle se bo pomaknil navzdol preko igle in se bo zaskočil.
Press the pump once quickly while inhaling through the nose.
Enkrat kratko pritisnite na pršilo in hkrati vdihnite skozi nos.
Press the sticky side of the patch firmly into place for about 10 seconds.
Lepljivo stran obliža približno 10 sekund močno pritisnite na kožo.
Press the sticky side of the patch firmly into place.
Lepljivo stran obliža močno pritisnite na kožo.
Press the threaded tip of the pen into the outer needle cap and screw the outer needle cap on until it is firmly fixed.
Potisnite navojno konico injekcijskega peresnika v zunanji pokrovček igle in zasučite zunanji pokrovček igle dokler ni čvrsto pritrjen.
Press the yellow release button to release the blue injection button.
Pritisnite na rumeni sprožilni gumb, da s tem sprostite modri injekcijski gumb.
Pressing the Dose Knob more slowly may make it easier.
Počasnejše pritiskanje gumba za odmerjanje lahko olajša pritiskanje.
Pressing the Dose Knob quickly may make the Dose Knob harder to push.
Hitro pritiskanje gumba za odmerjanje lahko povzroči težje pritiskanje gumba za odmerjanje.
Pressing the pen down will insert the needle and automatically start the injection.
S pritiskanjem peresnika navzdol se igla vstavi in injiciranje se začne samodejno.
Pressure build-up may require venting.
Tlak se lahko poveča in morda ga boste morali sprostiti.
Pressure in the lower abdomen
pritisk v spodnjem delu trebuha;
Pressure should be applied with the fingers around the outer edges to ensure adhesion to the skin site.
S prsti pritisnite zunanje robove, da se sistem zanesljivo oprime kože.
Presumably through blockade of the renin- angiotensin-aldosterone system, co-administration of telmisartan tends to reverse the potassium loss associated with these diuretics.
Sočasno dajanje telmisartana deluje, predvidoma zaradi blokade renin- angiotenzin- aldosteronskega sistema, reverzibilno na izgubo kalija, do katere prihaja pri teh diuretikih.
Presumably through blockade of the renin- angiotensin-aldosterone system, co-administration of telmisartan tends to reverse the potassium loss associated with these diuretics.
Sočasno dajanje telmisartana deluje, predvidoma zaradi blokade renin-angiotenzin- aldosteronskega sistema, reverzibilno na izgubo kalija, do katere prihaja pri teh diuretikih.
Presumably through blockade of the renin- angiotensin-aldosterone system, co-administration of telmisartan tends to reverse the potassium loss associated with these diuretics.
Sočasno dajanje telmisartana deluje, predvidoma zaradi blokade renin-angiotenzin-aldosteronskega sistema, reverzibilno na izgubo kalija, do katere prihaja pri teh diuretikih.
Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of telmisartan tends to reverse the potassium loss associated with these diuretics.
Sočasno dajanje telmisartana deluje, predvidoma zaradi blokade renin-angiotenzin- aldosteronskega sistema, reverzibilno na izgubo kalija, do katere prihaja pri teh diuretikih.
Preterm Infants
Nedonošenčki
Preterm infants (born after 27 weeks and less than 37 week pregnancy)
Nedonošenčki (rojeni po 27. in pred 37. tednom nosečnosti)
Preterm infants born after at least 24 weeks of gestational age
Nedonošenčki, rojeni po vsaj 24 tednih gestacijske starosti
Pretreatment sodium abnormalities (hyponatraemia or hypernatraemia) must be corrected prior to initiation with tolvaptan therapy.
Nenormalnosti natrija (hiponatriemija ali hipernatriemija) je treba pred uvedbo zdravljenja s tolvaptanom odpraviti.
Pretreatment with antihistimines and/or antipyretics prior to LEMTRADA administration may also be considered.
Poleg tega pride v poštev tudi premedikacija z antihistaminiki in/ali antipiretiki pred dajanjem zdravila LEMTRADA.
Pretreatment with multiple doses of rifampicin 600 mg followed by a single
Predzdravljenje z večkratnimi odmerki rifampicina 600 mg, ki jim je sledil en
Prevalence is significantly higher in Japanese patients when compared to non- Japanese patients.
Pogostnost je bistveno višja pri japonskih bolnikih v primerjavi z ne-japonskimi bolniki.
Prevenar 13 contains the same 7 serotypes included in Prevenar, using the same carrier protein CRM197.
Cepivo Prevenar 13 vsebuje istih 7 serotipov kot cepivo Prevenar na istem nosilnem proteinu CRM197.
Prevenar 13 is estimated to cover over 90% of serotypes causing antibiotic-resistant IPD.
Ocenjujejo, da cepivo Prevenar 13 pokriva več kot 90 % serotipov, ki povzročajo proti antibiotikom odporne invazivne pnevmokokne bolezni.
Prevenar 13 is used to protect children aged between six weeks and 17 years against invasive disease, pneumonia (infection of the lungs) and acute otitis media (infection of the middle ear) caused by
Zdravilo Prevenar 13 se uporablja za zaščito otrok, starih od šest tednov do 17 let, proti invazivni bolezni, pljučnici (okužbi pljuč) in akutnemu vnetju srednjega ušesa, ki ga povzroča bakterija
Prevenar 13 N=400-426
Prevenar 13 n = 400-426
Prevenar 13 pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Prevenar 13 cepivo proti pnevmokokom, polisaharidno, konjugirano (13-valentno, adsorbirano)
Prevenar 13 Relative to PPSV23,
Prevenar 13 v primerjavi s PPSV23,
Prevenar 13 vaccine schedule for infants and children previously vaccinated with Prevenar (7-valent) (Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F)
Shema cepljenja s cepivom Prevenar 13 za dojenčke in otroke, ki so bili predhodno cepljeni s cepivom Prevenar (7-valentno) (serotipi Streptococcus pneumoniae 4, 6B, 9V, 14, 18C, 19F in 23F)
Prevenar can be given at the same time as other childhood vaccines; in this case different injection sites should be used.
Otrok lahko dobi cepivo Prevenar skupaj z drugimi cepivi za otroke; v tem primeru bo zdravnik izbral različna mesta injiciranja.
Prevenar contains small amounts of polysaccharides (a type of sugar) extracted from the ‘capsule’ that surrounds the S. pneumoniae bacterium.
Zdravilo Prevenar vsebuje majhne količine polisaharidov (vrste sladkorja), pridobljenih iz „ovojnice“, ki obdaja bakterijo S. pneumoniae.
Prevenar was given at two, four, six and 12 to 15 months of age.
Cepljenje je bilo izvedeno v 2., 4., 6. in 12.–15. mesecu starosti.